7Baggers
Quarterly
Annual
    Unit: USD2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 
      
    		                      
      operating activities
    		                      
      net income
    		-83,187,000 -77,297,000 -53,530,000 -39,919,000 -87,385,000 -94,322,000 -79,437,000 -77,925,000 -73,420,000 -74,178,000 -72,388,000 -69,050,000 -61,801,000 -56,072,000 -41,041,000 -47,010,000 -29,787,000 11,272,000 -21,659,000 -19,893,000 -15,294,000 -16,217,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                      
      depreciation and amortization expense
    		1,101,000 1,017,000 878,000 844,000 729,000                  
      non-cash operating lease expense
    		525,000 262,000 680,000 443,000 400,000 477,000 439,000 451,000 286,000 286,000 286,000 287,000 272,000 248,000 243,000 245,000 257,000      
      equity-based compensation expense
    		29,948,000 26,470,000 25,963,000 26,245,000 30,462,000                  
      equity method investment loss and impairment
    		6,595,000                      
      changes in operating assets and liabilities
    		                      
      accounts receivable
    		5,891,000 -13,266,000 -8,468,000 -8,975,000 -9,599,000                  
      inventory
    		-2,205,000 -386,000 -2,108,000 -2,502,000 -2,113,000                  
      prepaid expenses and other current assets
    		347,000 -336,000 -477,000 -747,000 -1,793,000 -2,713,000 -2,770,000 2,322,000 -1,968,000 -2,204,000 2,114,000 222,000 1,729,000 -4,308,000 -887,000 -111,000 697,000 -2,831,000 480,000 4,000 1,142,000 -3,020,000 
      other assets
    		-656,000 -5,917,000 -461,000 -759,000 -78,000 -152,000 -478,000 35,000 -243,000 -195,000 234,000 -60,000 82,000 -258,000 -232,000 328,000 -545,000 -562,000 0 0 -281,000 363,000 
      accounts payable
    		2,861,000 2,664,000 1,580,000 745,000 -385,000 2,065,000 2,574,000 -4,082,000 -753,000 3,006,000 2,395,000 537,000 -1,770,000 926,000 -1,406,000 1,675,000 879,000 286,000 155,000 -708,000 -1,037,000 497,000 
      accrued expenses
    		-29,336,000 36,112,000 9,248,000 1,097,000 -9,625,000 13,963,000 5,012,000 7,186,000 -10,255,000 -217,000 8,104,000 10,133,000 -4,695,000 1,299,000 5,638,000 2,618,000 357,000 3,626,000 3,007,000 1,670,000 -2,358,000 1,271,000 
      lease liability
    		-643,000 -17,995,000 -493,000 -491,000 -568,000 -430,000 -417,000 -55,000 -391,000 -558,000 -111,000 -146,000 -44,000 -349,000 -342,000 -342,000 -355,000      
      net cash from operating activities
    		-68,759,000 -29,500,000 -25,379,000 -41,790,000 -78,930,000 -62,705,000 -50,461,000 -47,811,000 -61,818,000 -54,200,000 -19,604,000 -39,071,000 -48,688,000 -46,316,000 -26,929,000 -33,528,000 -21,104,000 15,066,000 -14,700,000 -16,159,000 -16,398,000 -16,063,000 
      investing activities
    		                      
      capital expenditures
    		-30,000 -1,052,000 -1,847,000 -975,000 -577,000 2,302,000 -3,622,000 -3,088,000 -2,977,000 -1,756,000 -3,528,000 -2,525,000 -2,387,000 -1,504,000 -335,000 -132,000 -45,000 -54,000 -167,000 -261,000 -160,000  
      free cash flows
    		-68,789,000 -30,552,000 -27,226,000 -42,765,000 -79,507,000 -60,403,000 -54,083,000 -50,899,000 -64,795,000 -55,956,000 -23,132,000 -41,596,000 -51,075,000 -47,820,000 -27,264,000 -33,660,000 -21,149,000 15,012,000 -14,867,000 -16,420,000 -16,558,000  
      equity method investment
    		 0 0 0 -8,235,000                  
      purchases of marketable securities
    		 -80,844,000 -45,025,000 -85,590,000 -73,642,000 -266,448,000 -96,664,000 -144,464,000 -68,148,000 -413,097,000 0 -44,711,000 -23,242,000 -86,560,000 -77,966,000 -54,524,000 -86,373,000 -250,727,000 -127,396,000    
      proceeds from sale and maturity of marketable securities
    		73,423,000 101,041,000 75,520,000 98,104,000 103,917,000                  
      net cash from investing activities
    		73,393,000 14,145,000 28,648,000 289,000 21,463,000 -159,205,000 34,599,000 60,756,000 98,604,000 -355,010,000 86,232,000 26,757,000 26,424,000 56,181,000 35,785,000 22,544,000 -30,918,000 -222,781,000 -127,563,000 -68,328,000 -160,000 -130,000 
      financing activities
    		                      
      treasury stock
    		-12,869,000 -523,000 -499,000 -919,000 -6,497,000 -253,000 -264,000 -352,000 -1,931,000 0 -212,000            
      proceeds from stock option exercises
    		2,260,000 1,176,000 1,790,000 4,290,000 5,945,000 24,000 22,000 10,000 83,000 298,000 377,000 135,000 1,167,000 244,000 425,000 129,000 359,000 381,000 428,000 78,000 6,000 20,000 
      net cash from financing activities
    		-10,609,000 653,000 1,291,000 3,371,000 -552,000 299,071,000 -242,000 -342,000 -1,848,000 298,000 340,231,000 -88,000 261,000 244,000 425,000 129,000 359,000 269,973,000 428,000 78,000 6,000 20,000 
      net increase in cash and cash equivalents
    		-5,975,000 -14,702,000 4,560,000 -38,130,000 -58,019,000 77,161,000 -16,104,000 12,603,000 34,938,000       -10,855,000 -51,663,000 62,258,000 -141,835,000 -84,409,000 -16,552,000 -16,173,000 
      cash and cash equivalents including restricted cash, beginning of period
    		70,375,000 0 0 0 176,666,000 0 0 0 68,068,000 0 0 0 104,526,000 0 0 0 147,654,000 0 0 0 328,192,000  
      cash and cash equivalents including restricted cash, end of period
    		64,400,000 -14,702,000 4,560,000 -38,130,000 118,647,000 77,161,000 -16,104,000 12,603,000 103,006,000 -408,912,000 406,859,000 -12,402,000 82,523,000 10,109,000 9,281,000 -10,855,000 95,991,000 62,258,000 -141,835,000 -84,409,000 311,640,000  
      supplemental non-cash disclosure
    		                      
      milestone payment for first commercial sale of gomekli included in accrued expenses as of march 31, 2025
    		6,000,000                      
      equity method investment loss
    		 1,390,000 1,809,000 1,776,000 1,025,000                  
      deferred revenue
    		 17,782,000 0                    
      payment for intangible asset
    		 -5,000,000 0                    
      proceeds from issuance of common stock in underwritten public offering, net of issuance costs
    		                      
      proceeds from issuance of common stock to gsk
    		         0             
      proceeds from issuance of common stock in private placement, net of issuance costs
    		         0             
      proceeds from issuance of common stock under at-the-market offering, net of issuance costs
    		         0             
      right-of-use assets obtained in exchange for operating lease obligations
    		 0 0   0 0   0 0            
      milestone payment for first commercial sale of ogsiveo included in accrued expenses as of december 31, 2023
    		                      
      non-cash investing activities
    		                      
      other liabilities
    		                      
      depreciation expense
    		      494,000 382,000 253,000 255,000 212,000 190,000 108,000 146,000 119,000 115,000 110,000 110,000 95,000 74,000 70,000 65,000 
      stock compensation expense
    		      23,098,000 22,974,000 23,395,000 18,924,000 18,518,000 18,429,000 17,094,000 11,882,000 10,712,000 8,795,000 7,055,000 3,042,000 3,043,000 2,599,000 1,350,000 950,000 
      equity investment loss
    		      1,024,000 901,000 1,278,000 680,000 1,486,000 387,000 337,000 301,000 267,000 159,000 261,000 146,000 130,000 229,000 100,000 113,000 
      equity investments
    		      0   0 0       0 0    
      proceeds from sale and maturity of debt securities
    		      134,885,000 208,308,000 172,529,000 59,843,000 89,760,000 78,193,000 52,053,000 144,245,000 114,086,000 77,200,000 55,500,000      
      equity investment
    		        -2,800,000              
      proceeds from issuance of common stock upon closing of follow-on offering, net of issuance costs
    		                      
      net decrease in cash and cash equivalents
    		           -12,402,000 -22,003,000          
      supplemental non-cash items not included above resulting from the adoption of asc 842
    		                      
      initial recognition of operating lease right of use asset
    		                      
      initial recognition of lease liabilities
    		                      
      other long-term liabilities
    		             -131,000 0 0 -33,000 68,000     
      shares of common stock repurchased to satisfy tax withholding obligations
    		            -906,000          
      deferred rent
    		                  -91,000 -90,000 -90,000 -85,000 
      proceeds from issuance of common stock, net of issuance costs
    		                     0 
      proceeds from issuance of series a convertible preferred shares, net of issuance costs
    		                     0 
      proceeds from issuance of series b convertible preferred shares, net of issuance costs
    		                     0 
      other
    		                      
      ​
    		                      
      unrealized loss on marketable securities
    		                      
      non-cash license expense
    		                      
      purchases of property and equipment
    		                      
      investment in mapkure
    		                      
      cash and cash equivalents, beginning of period
    		                      
      cash and cash equivalents, end of period
    		                      
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.